Immuron (IMRN) Capital Expenditures (2016 - 2023)
Immuron (IMRN) posted quarterly Capital Expenditures of $276867.6 for Q2 2023, up 178.22% year-over-year from $99512.3 in Q2 2022, and up 4017.75% quarter-over-quarter from -$7067.0 in Q4 2022.
Immuron (IMRN) Capital Expenditures (2016 - 2023) Analysis & Trends
Immuron's Capital Expenditures history runs 7 years deep, the most recent figure standing at $276867.6 for Q2 2023.
- In Q2 2023, Capital Expenditures rose 178.22% year-over-year to $276867.6; the TTM figure through Jun 2023 stood at -$88991.6 (up 77.76% YoY), while the FY2025 annual figure was -$3.0 million, down 1556965.64% from the prior year.
- Capital Expenditures for Q2 2023 stood at $276867.6, up from -$7067.0 in the prior quarter.
- The five-year high for Capital Expenditures was $276867.6 in Q2 2023, with the low at -$353939.0 in Q2 2022.
- The 5-year median for Capital Expenditures is -$5741.6 (2020), against an average of -$15079.8.
- The sharpest annual moves came in 2022 and 2023: Capital Expenditures tumbled 919.92% in 2022, then soared 178.22% in 2023.
- Immuron's Capital Expenditures stood at -$864.0 in 2019, then sank by 667.36% to -$6630.0 in 2020, then rose by 26.8% to -$4853.3 in 2021, then tumbled by 45.61% to -$7067.0 in 2022, then soared by 4017.75% to $276867.6 in 2023.
- Business Quant data shows IMRN's Capital Expenditures at $276867.6 in Q2 2023, -$7067.0 in Q4 2022, and -$353939.0 in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 251.02 Mn |
| 10 | Immuron | 6.75 Mn | 6.73 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 276,867.65 |
| Jun 30, 2023 | 276,867.65 |
| Dec 31, 2022 | -7,067.00 |
| Dec 31, 2022 | -7,067.00 |
| Jun 30, 2022 | -353,938.98 |
| Jun 30, 2022 | -353,938.98 |
| Dec 31, 2021 | -4,853.28 |
| Dec 31, 2021 | -4,853.28 |
| Jun 30, 2021 | -34,702.53 |
| Jun 30, 2021 | -34,702.53 |
| Dec 31, 2020 | -6,630.00 |
| Dec 31, 2020 | -6,630.00 |
| Jun 30, 2020 | 10,549.65 |
| Jun 30, 2020 | 10,549.65 |
| Dec 31, 2019 | -864.00 |
| Dec 31, 2019 | -864.00 |
| Dec 31, 2017 | -1,698.97 |
| Dec 31, 2017 | -1,698.97 |
| Dec 31, 2016 | 1,416.72 |
| Dec 31, 2016 | 1,416.72 |